- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Approves Epysqli as Second Soliris Biosimilar
The FDA approves Samsung Bioepis’ Epysqli (eculizumab-aagh), marking the second US approval for a biosimilar referencing Soliris (eculizumab).
The FDA approved Epysqli (eculizumab-aagh), a biosimilar developed by Samsung Bioepis that references Soliris (eculizumab), for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).1
According to Johns Hopkins Medicine, paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening blood disorder characterized by the destruction of red blood cells, blood clot formation, and impaired bone marrow function. It is closely associated with aplastic anemia. | Image credit: Anusorn - stock.adobe.com
The approval marked the second for an eculizumab biosimilar, following the May 2024 approval of Bkemv (eculizumab-aeeb).2 Epysqli is also the eighth US biosimilar approval for Samsung Bioepis, following biosimilars for etanercept, infliximab, adalimumab, trastuzumab, bevacizumab, ranibizumab, aflibercept, and ustekinumab.3
“The FDA approval of Epysqli as a biosimilar to Soliris marks an important milestone for PNH and aHUS communities since biosimilars have a potential to positively impact patients and healthcare systems by reducing healthcare costs and improving access to treatments,” Christopher Hansung Ko, President and CEO at Samsung Bioepis, said in a statement.1 “Our mission has been, and always will be improving the lives of patients by providing quality-assured, safe and effective biologic medicines, and our work to fulfill this mission is expanding into rare disease areas where patients continue to suffer from limited access to life-enhancing medicines.”
The FDA’s approval of Epysqli was based on extensive evidence showing it is very similar to Soliris, with no significant differences in safety, purity, and potency. A phase 1, randomized, double-blind, 3-arm, parallel group, single-dose study in healthy volunteers (NCT03722329) demonstrated pharmacokinetic (PK) equivalence and comparable pharmacodynamic (PD), safety, tolerability, and immunogenicity profiles between Epysqli and the reference product. Additionally, a phase 3, randomized, double-blind, multicenter, cross-over study in patients with PNH (NCT04058158) showed clinical equivalence in efficacy, safety, PK, and immunogenicity between the 2 drugs.
Eculizumab, a monoclonal antibody and anti-C5 complement inhibitor, is a well-established treatment for PNH and aHUS, rare diseases with an estimated US prevalence of around 50,000 and 5,000 respectively.4 However, approximately 70% of eculizumab-treated patients with PNH are not dosed according to the label, and two-thirds discontinue treatment within an average of 1.5 years, often due to the high cost of treatment.
Biosimilars, which are highly similar to and have no clinically meaningful differences from an existing FDA-approved biologic, have the potential to alleviate financial burdens on the health care system and improve access to biologic therapies. These drugs must meet the same rigorous standards for pharmaceutical quality, safety, and efficacy as their reference products.
Epysqli was approved by the European Commission in May 2023 as the first eculizumab biosimilar in Europe.5 The biosimilar is also approved in the Republic of Korea.
Samsung Bioepis noted that the biosimilar was not approved to treat patients with Shiga toxin E coli–related hemolytic uremic syndrome.
Reference
1. FDA Approves Samsung Bioepis’ EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab). News release. Samsung Bioepis; July 22, 2024. Accessed July 22, 2024. https://www.globenewswire.com/news-release/2024/07/22/2916428/0/en/FDA-Approves-Samsung-Bioepis-EPYSQLI-eculizumab-aagh-as-a-Biosimilar-to-Soliris-eculizumab.html
2. Jeremias S. FDA Approves First Eculizumab Biosimilar. The Center for Biosimilars®. May 29, 2024. Accessed July 22, 2024. https://www.centerforbiosimilars.com/view/fda-approves-first-eculizumab-biosimilar
3. Our products. Samsung Bioepis. Updated July 22, 2024. Accessed July 22, 2024. https://www.samsungbioepis.com/en/product/gate.do
4. National Center for Advancing Translational Sciences. Paroxysmal nocturnal hemoglobinuria. Accessed July 22, 2024. https://rarediseases.info.nih.gov/diseases/7337/index
5. Jeremias S. Samsung Bioepis' Eculizumab Biosimilar Approved in Europe. The Center for Biosimilars. May 31, 2023. Accessed July 22, 2024. https://www.centerforbiosimilars.com/view/first-hematology-biosimilar-approved-in-europe
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
